Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma

被引：4
|
作者：
Shimabukuro-Vornhagen, A. [1 ]
Josting, A. [1 ]
Huebel, K. [1 ]
Scheid, C. [1 ]
Dietlein, M. [1 ]
Engert, A. [1 ]
Schnell, R. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8615
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [2] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [3] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [4] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
  • [5] Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma
    Shah, Jatin
    Wang, Wenquan
    Harrough, V. Douglas
    Saville, Wayne
    Meredith, Ruby
    Shen, Sui
    Mueh, John
    Li, John
    Jasthy, Sri
    Maggass, Gregory
    Mckay, Charles
    Krumdieck, Richard
    Tharp, Morgan
    Winter, Christine
    Gregory, Stephanie
    Buchholz, William
    Awasthi, Sanjay
    Jacobs, Samuel
    Chung, Harold
    Egner, James
    Lobuglio, Albert F.
    Forero, Andres
    LEUKEMIA & LYMPHOMA, 2007, 48 (09) : 1736 - 1744
  • [6] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, I. W.
    Kahl, B. S.
    Frey, E. C.
    Bianco, J. A.
    Hammes, R. J.
    Webb, J.
    Swinnen, L. J.
    Sgouros, G.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
  • [7] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [8] Comparison between BEAM and Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-BEAM as conditioning regimen before autologous stem cell transplantation in patients with non-Hodgkin B-Cell Lymphoma
    Chic Acevedo, C.
    Garcia Torres, E.
    Llamas Poyato, M. J.
    Rodriguez, G.
    Martin, C.
    Rojas, R.
    Serrano, J.
    Tabares, S.
    Vallejo, J. A.
    Sanchez, J.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S224 - S224
  • [9] Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
    Winter, JN
    CLINICAL LYMPHOMA, 2004, 5 : S22 - S26
  • [10] Minimum tolerable interval of 90yttrium ibritumomab-tiuxetan to autologous stem cell transplantation after high-dose chemotherapy with carmustin, etoposide, cytarabine, and melphalan for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Hasenkamp, Justin
    Hess, Georg
    Hertenstein, Bernd
    Dreger, Peter
    Uharek, Lutz
    Gramatzki, Martin
    Schubert, Joerg
    Wulf, Gerald
    Truemper, Lorenz
    Schmitz, Norbert
    Glass, Bertram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345